Navigation Links
Northwestern University and ACORN Commence National Enrollment for Metastatic Breast Cancer Study
Date:11/12/2007

ctivity of sorafenib, this clinical trial will randomize patients with metastatic breast cancer to receive weekly paclitaxel or the combination of paclitaxel and sorafenib. This trial will determine if an oral multi-kinase inhibitor adds to the clinical benefit derived from chemotherapy alone in patients with metastatic breast cancer."

Dr. Lee Schwartzberg directs all clinical research initiatives and provides clinical oversight and management of ACORN. "Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals and ACORN seek to advance the standards of cancer care by making the most promising molecules available to the broadest demographic population possible. ACORN's network of community oncology practices along with its centralized clinical trial management services helps make that goal possible," remarked Dr. Schwartzberg.

In addition to this clinical trial, researchers are studying Nexavar in pivotal trials in hepatocellular cancer, metastatic melanoma and non-small cell lung cancer.

Northwestern University

Northwestern University combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. It provides students and faculty exceptional opportunities for intellectual, personal, and professional growth in a setting enhanced by the richness of Chicago. Northwestern is recognized both nationally and internationally for the quality of its educational programs at all levels.

Accelerated Community Oncology Research Network, Inc. (ACORN)

The mission of ACORN is to significantly enhance the speed, accuracy, and productivity of conducting clinical research in the community oncology setting. The ACORN Contract Research Organization (CRO) enrolls research sites, provides contract and budgeting services, fosters the accrual of subjects at the site level, collects data and monitors its accuracy, and works seamlessly as an extension of both the sponsoring organizatio
'/>"/>

SOURCE Accelerated Community Oncology Research Network
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Evanston Northwestern Healthcare Wins Award For Patient Safety
2. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
3. Northwestern Memorial Hospital Completes Move Into Its New Prentice Womens Hospital
4. Northwestern exposing most deadly infectious diseases in 3-D
5. University of Iowa professor identifies new eating disorder
6. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. University of Texas Study Details Lengthy Payment Delays for Medicare Part D Prescription Drug Claims, Confirming Need for Legislative Fix
8. Tulane University to receive $14M for international HIV/AIDS program
9. University of Nevada School of Medicine Professor Confirms Accuracy Through Validation Study Using the CSI Health Station Model 6K
10. Boston University School of Medicine researcher recipient of Memory Ride Grant
11. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., study suggests , , THURSDAY, Jan. 8 (...rongly they would react to racist acts, a new Cana...y participants at York University, in Toronto, sti... person rather than a black one, even after their ...rson when he left the room. , "And the racist...
(Date:1/8/2009).../ -- Allscripts-Misys Healthcare,Solutions, Inc.,...llscripts or,the Company), today announced its fi...d November 30, 2008. , (Logo: http://www.n...) , The Company,s results for the three and...ts from legacy Allscripts for the period of Octobe...
(Date:1/8/2009)...wire/ -- A new educational Web site offers expert ...ical products and medical devices from the Agency ...Education and Research on Therapeutics (CERTs), a ...eading research centers nationwide. The Clinician...AIN ) http://www.chainonline.org links clinician...
(Date:1/8/2009)...Call/ -- Heska Corporation (Nasdaq: HSKA ) annou... Heska Corporation Invites You to Join Its Fourth... Conference Call on the Web, When: Monda... www.heska.com (click on the Q4 and Year-End 200...age of this website)., How: Live over t...
Breaking Medicine News(10 mins):Health News:Many Turn Blind Eye to Racism 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
...esearchers say eating fish could help keep ones mi... high intake of cholesterol and saturated fat have...middle age. More and more research is showing what... for dementia. For example, studies have shown tha...
... risk factor, which accounts for about half of the...e is now a more dependable, less expensive test to... the NMP22 tumor marker assay in 1,331 patients at...s found that of the 79 patients shown to have blad...
...ound in the air in many inner-city homes could be ...n children say researchers. According to researche...ously exposed to the allergy-causing substance fou... the air and exposure increases their risk for dev...
...sted early onset wheezing is associated with high ...d bronchial hyper-responsiveness. Children with th... more severe asthma. However, some children who de...ith the same characteristics as those who begin wh...
Other Medicine News:
(Date:1/7/2009)... ImQuest Life Sciences announced today the success...nd Drug Administration to initiate human clinical ...r IQP-0410. ImQuest anticipates initiating their P...410 is a novel small molecule inhibitor of HIV whi...criptase inhibitor (NNRTI). The compound possesses...
(Date:1/6/2009)...from prior U.S., U.K. and China Trials , , SAN .... (VTI), a development stage company targeting liv... begun for a randomized, controlled, multi-center,...orporeal Liver Assist Device (ELAD) as a treatment... three protocols. The study is open for enrollment...
(Date:1/6/2009)...ewswire/ -- Sequella, Inc., a clinical-stage bioph...ic potential, announced today that SQ109, its lead...(TB), was the first drug approved for evaluation i...port Vaccine Company LLC and Quintiles Transnation...e of Allergy and Infectious Diseases (NIAID), Nati...
(Date:1/5/2009)...ne Pharmaceuticals announced today that it has ini...otein kinase inhibitor, CX-4945, in patients with ...tiple myeloma. The primary endpoints of the oral d...tolerance and PK properties of CX-4945 and to sele...dition, multiple mechanism-related pharmacodynamic...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 1PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 1China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 2China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 3China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 5China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 6China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 7China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 8China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 9China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 10China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 11Sentillion Appoints New UK Sales Manager 30669 1Sentillion Appoints New UK Sales Manager 30669 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 1Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 3Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 4
...gress of European Hematology,Association (EHA) -, ...ll/ --,Immunomedics, Inc. , a biopharmaceutical co...to treat cancer and other serious,diseases, today ...,of EHA in Vienna, Austria, showed positive respon...treated with a new,radioimmunotherapy (RAIT) using...
...--Jun 11, 2007 - Geron,Corporation (Nasdaq:GERN) t...s indicating that GRNOPC1, the company,s human,emb...treatment of,spinal cord injury, evades a direct a...ron scientist Ross Okamura at the Federation of,Cl...the findings,could mean that patients treated with...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: